Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226,220,429
-
Total 13F shares
-
71,621,156
-
Share change
-
+2,871,455
-
Total reported value
-
$1,860,741,066
-
Put/Call ratio
-
92%
-
Price per share
-
$25.98
-
Number of holders
-
114
-
Value change
-
+$73,711,322
-
Number of buys
-
67
-
Number of sells
-
36
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q4 2019
As of 31 Dec 2019,
Allogene Therapeutics, Inc. - Common Stock (ALLO) was held by
114 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
71,621,156 shares.
The largest 10 holders included
TPG Group Holdings (SBS) Advisors, Inc., Capital Research Global Investors, BlackRock Inc., FMR LLC, VANGUARD GROUP INC, Capital International Investors, Capital World Investors, VV Manager LLC, PRICE T ROWE ASSOCIATES INC /MD/, and REGENTS OF THE UNIVERSITY OF CALIFORNIA.
This page lists
114
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.